Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
24 hedge funds and large institutions have $4.67M invested in Seelos Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 7 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
4% more funds holding
Funds holding: 23 → 24 (+1)
5% more capital invested
Capital invested by funds: $4.46M → $4.67M (+$205K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
+$632K |
| 2 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$187K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$176K |
| 4 |
Two Sigma Advisers
New York
|
+$108K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$25.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$363K |
| 2 |
TAM
Tocqueville Asset Management
New York
|
-$133K |
| 3 |
VF
Virtu Financial
New York
|
-$97K |
| 4 |
SIM
Spark Investment Management
New York
|
-$21.5K |
| 5 |
DC
Davenport & Co
Richmond,
Virginia
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
26
Virtu Financial
New York
| – | -$97K | -25 | Closed |
|
|
DC
27
Davenport & Co
Richmond,
Virginia
| – | -$20K | -5 | Closed |
|
|
KJHP
28
K.J. Harrison & Partners
Toronto,
Ontario, Canada
| – | -$20K | -5 | Closed |
|
29
Jane Street
New York
| – | -$12K | -3 | Closed |
|
|
PA
30
Procyon Advisors
Shelton,
Connecticut
| – | -$5K | -1 | Closed |
|
31
UBS Group
Zurich,
Switzerland
| – | -$3.59K | -1 | Closed |
|
|
PAM
32
Panagora Asset Management
Boston,
Massachusetts
| – | -$1K | – | – |
|
|
PAG
33
Private Advisor Group
Morristown,
New Jersey
| – | -$1K | – | – |
|
SEEL Hedge Fund Activity: Q3 2020 in Review
24 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2020, worth a combined $4.67M — up 4.6% from $4.46M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SEEL positions and 7 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Uniplan Investment Counsel, adding an estimated $632K. The largest seller was Renaissance Technologies, cutting an estimated $363K.
- 24 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2020, up from 23 in Q2 2020.
- Funds reported $4.67M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2020, up 4.6% quarter-over-quarter.
- 8 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2020 and 7 closed out, a net change of +1 holder.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2020 was Uniplan Investment Counsel, an estimated $632K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2020 was Renaissance Technologies, an estimated $363K sold.
Based on aggregated 13F filings for Q3 2020.